Anika Therapeutics/$ANIK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Anika Therapeutics
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
- Ticker
- $ANIK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 235
- Headquarters
- Bedford, United States
- Website
- www.anika.com
ANIK Metrics
BasicAdvanced
$195M
-
-$0.13
-
-
Price and volume
Market cap
$195M
52-week high
$22.88
52-week low
$9.01
Average daily volume
114K
Financial strength
Current ratio
3.856
Quick ratio
2.59
Long term debt to equity
0.179
Total debt to equity
0.179
Profitability
EBITDA (TTM)
2.92
Gross margin (TTM)
63.40%
Net profit margin (TTM)
-1.43%
Operating margin (TTM)
-2.11%
Effective tax rate (TTM)
74.27%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-0.86%
Return on equity (TTM)
-0.18%
Valuation
Price to revenue (TTM)
1.607
Price to book
1.42
Price to tangible book (TTM)
1.52
Price to free cash flow (TTM)
86.414
Free cash flow yield (TTM)
1.16%
Free cash flow per share (TTM)
0.168
Growth
Revenue change (TTM)
9.42%
Earnings per share change (TTM)
-94.29%
3-year revenue growth (CAGR)
-8.91%
10-year revenue growth (CAGR)
1.58%
3-year earnings per share growth (CAGR)
-57.30%
10-year earnings per share growth (CAGR)
-25.03%
What the Analysts think about ANIK
Analyst ratings (Buy, Hold, Sell) for Anika Therapeutics stock.
Analyst projections of the future price of Anika Therapeutics stock.
ANIK Financial Performance
Revenues and expenses
ANIK Earnings Performance
Company profitability
Upcoming events
No upcoming events
ANIK News
AllArticlesVideos
Funds containing ANIK
Fund name | Fund size | $ANIK weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.